Session Chair Profile

M.D., Ph.D., CSO and Co-Founder, Genomenon, Inc.

Dr. Kiel is Founder and Chief Science Officer at Genomenon where he oversees the company’s scientific direction and product development. Prior to starting Genomenon, Mark completed his residency in Clinical Pathology in 2014 at the University of Michigan. While at Michigan, he completed a fellowship in Molecular Diagnostics and devised the informatics framework for clinical next-generation sequencing in the Molecular Diagnostics Laboratory. While a post-doctoral researcher under Drs. Kojo Elenitoba-Johnson and Megan Lim, he made significant contributions to the field of Hematopathology including genomic profiling of lymphoid malignancies for which he was awarded the Benjamin Castleman Award. During his doctoral studies with Sean Morrison, he made seminal contributions to the study of hematopoietic stem cells for which he was awarded the Weintraub International Graduate Student Award and the ProQuest Distinguished Dissertation Award.

Session Abstract

Session Synopsis: Identifying content for genomic panels is a daunting challenge for pharma, clinicians and vendors. You want to balance the broadest selection of biomarkers that can have diagnostic impact and also inform future associations to cost/size. Dr. Weigman will highlight an approach that leverages mining millions of full text genomic articles to identify disease-gene-variant relationships within a concise platform that significantly reduces inclusion time and allows for selection of markers based on treatment, prognosis and monitoring.